Company profile
Intellia Therapeutics, Inc.
NASDAQ:NTLABiotechnology: In Vitro & In Vivo Diagnostic Substances
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Lonvoguran | phase3 | — | 1 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06672237 | phase3 | recruiting | 2024-11-22 | 2027-07-01 | Intellia Therapeutics | A Phase 3 Study of NTLA-2001 in ATTRv-PN |
| NCT06634420 | phase3 | active_not_recruiting | 2025-01-15 | 2026-02-10 | Intellia Therapeutics | HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE) |
| NCT06128629 | phase3 | recruiting | 2023-12-13 | 2027-12-01 | Intellia Therapeutics | MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM) |
| NCT05120830 | phase1_2 | active_not_recruiting | 2021-12-10 | 2024-04-04 | Intellia Therapeutics | NTLA-2002 in Adults With Hereditary Angioedema (HAE) |
| NCT06622668 | phase1_2 | withdrawn | 2024-11-20 | 2025-01-09 | Intellia Therapeutics | NTLA-3001 in Adults with Alpha-1 Antitrypsin Deficiency-Associated Lung Disease |
FDA applications (0)
No records yet.